Metraipolis › archive › dc_3181c28d60ec

Novel modelling approaches to predict the role of antivirals in reducing influenza transmission — Europe PMC PMID:36608108

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/36608108
DOI
10.1371/journal.pcbi.1010797
License (as archived)
CC0-1.0
Archived
2026-10-08T02:59:49.933Z
SHA-256 of the archived text
1e9bc7278364a8998a47b26cbbb5c18cf34a536426692e56b5caf4454eed50dd
Stable URL of this page
https://metraipolis.com/documento/dc_3181c28d60ec

How to cite

Novel modelling approaches to predict the role of antivirals in reducing influenza transmission — Europe PMC PMID:36608108 — Europe PMC (en), https://europepmc.org/article/MED/36608108 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_3181c28d60ec (Metraipolis archive dc_3181c28d60ec, sha256 1e9bc7278364a8998a47b26cbbb5c18cf34a536426692e56b5caf4454eed50dd)
BibTeX
@misc{dc3181c28d60ec,
  title = {Novel modelling approaches to predict the role of antivirals in reducing influenza transmission — Europe PMC PMID:36608108},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36608108},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_3181c28d60ec; sha256 1e9bc7278364a8998a47b26cbbb5c18cf34a536426692e56b5caf4454eed50dd},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36608108. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

To aid understanding of the effect of antiviral treatment on population-level influenza transmission, we used a novel pharmacokinetic-viral kinetic transmission model to test the correlation between nasal viral load and infectiousness, and to evaluate the impact that timing of treatment with the antivirals oseltamivir or baloxavir has on influenza transmission. The model was run under three candidate profiles whereby infectiousness was assumed to be proportional to viral titer on a natural-scale, log-scale, or dose-response model. Viral kinetic profiles in the presence and absence of antiviral treatment were compared for each individual (N = 1000 simulated individuals); subsequently, viral transmission mitigation was calculated. The predicted transmission mitigation was greater with earlier administration of antiviral treatment, and with baloxavir versus oseltamivir. When treatment was initiated 12-24 hours post symptom onset, the predicted transmission mitigation was 39.9-56.4% for baloxavir and 26.6-38.3% for oseltamivir depending on the infectiousness profile. When treatment was initiated 36-48 hours post symptom onset, the predicted transmission mitigation decreased to 0.8-28.3% for baloxavir and 0.8-19.9% for oseltamivir. Model estimates were compared with clinical data from the BLOCKSTONE post-exposure prophylaxis study, which indicated the log-scale model for infectiousness best fit the observed data and that baloxavir affords greater reductions in secondary case rates compared with neuraminidase inhibitors. These findings suggest a role for baloxavir and oseltamivir in reducing influenza transmission when treatment is initiated within 48 hours of symptom onset in the index patient.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS computational biology, 2023 (prima pubblicazione 2023-01-06).
Identificativi: PMID 36608108 · PMCID PMC9876374 · DOI 10.1371/journal.pcbi.1010797.
Descrittori MeSH principali: Thiepins; Influenza, Human.
Pagina: https://europepmc.org/article/MED/36608108 — https://doi.org/10.1371/journal.pcbi.1010797. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-08T02:29:02.983Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.